Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types

Recent advances in human immunology have led to the identification of novel immune cell subsets and the biological function of many of these subsets has now been identified. The recent US Food and Drug Administration approval of several immunotherapeutics for the treatment of a variety of cancer types and the results of ongoing immunotherapy clinical studies requires a more thorough interrogation of the immune system. We report here the use of flow cytometry-based analyses to identify 123 immune cell subsets of peripheral blood mononuclear cells. The use of these panels defines multiple differences in younger (< 40 years) vs. older (≥ 40 years) individuals and between aged-matched apparently healthy individuals and metastatic cancer patients, aspects not seen in the analysis of the following standard immune cell types: CD8, CD4, natural killer, natural killer-T, regulatory T, myeloid derived suppressor cells, conventional dendritic cells (DCs), plasmacytoid DCs and B cells. The use of these panels identifying 123 immune cell subsets may aid in the identification of patients who may benefit from immunotherapy, either prior to therapy or early in the immunotherapeutic regimen, for the treatment of cancer or other chronic or infectious diseases.

[1]  Greg Finak,et al.  State‐of‐the‐Art in the Computational Analysis of Cytometry Data , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[2]  Feng Jiang,et al.  Differential miRNA expressions in peripheral blood mononuclear cells for diagnosis of lung cancer , 2015, Laboratory Investigation.

[3]  G. Acharya,et al.  Gene expression profile in cardiovascular disease and preeclampsia: a meta-analysis of the transcriptome based on raw data from human studies deposited in Gene Expression Omnibus. , 2015, Placenta.

[4]  I. Lossos,et al.  HGAL localization to cell membrane regulates B-cell receptor signaling. , 2015, Blood.

[5]  Ruth R. Montgomery,et al.  CyTOF supports efficient detection of immune cell subsets from small samples. , 2014, Journal of immunological methods.

[6]  I. Lowy,et al.  Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab , 2014, Journal of Immunotherapy for Cancer.

[7]  L. Sengeløv,et al.  Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer , 2014, Cancer Immunology, Immunotherapy.

[8]  V. Bronte,et al.  Myeloid‐derived suppressor cell heterogeneity in human cancers , 2014, Annals of the New York Academy of Sciences.

[9]  P. Dessen,et al.  PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation , 2014, The Journal of experimental medicine.

[10]  S. Steinberg,et al.  A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates , 2014, Cancer Immunology, Immunotherapy.

[11]  C. Castelo-Branco,et al.  The immune system and aging: a review , 2014, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[12]  E. Plimack,et al.  PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection , 2013, Cancer Immunology Research.

[13]  J. Kuiper,et al.  T-Cell Immunoglobulin and Mucin Domain 3 Acts as a Negative Regulator of Atherosclerosis , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[14]  D. Serraino,et al.  Cancer, aging and immune reconstitution. , 2013, Anti-cancer agents in medicinal chemistry.

[15]  George C Tseng,et al.  Peripheral Blood Mononuclear Cell Gene Expression Profiles Predict Poor Outcome in Idiopathic Pulmonary Fibrosis , 2013, Science Translational Medicine.

[16]  F. Guadagni,et al.  Effects of conventional therapeutic interventions on the number and function of regulatory T cells , 2013, Oncoimmunology.

[17]  H. Groen,et al.  Arginase-1 mRNA expression correlates with myeloid-derived suppressor cell levels in peripheral blood of NSCLC patients. , 2013, Lung cancer.

[18]  M. Calaminici,et al.  Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Verschoor,et al.  Blood CD33(+)HLA-DR(−) myeloid-derived suppressor cells are increased with age and a history of cancer , 2013, Journal of leukocyte biology.

[20]  L. Xerri,et al.  PD-1 is a novel regulator of human B-cell activation. , 2013, International immunology.

[21]  I. Lowy,et al.  T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment , 2013, Cancer Immunology, Immunotherapy.

[22]  T. Greten,et al.  Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies , 2013, Cancer Immunology, Immunotherapy.

[23]  S. Wong,et al.  Increased Myeloid-Derived Suppressor Cells in Gastric Cancer Correlate with Cancer Stage and Plasma S100A8/A9 Proinflammatory Proteins , 2013, The Journal of Immunology.

[24]  A. Larbi,et al.  NK Cells in Healthy Aging and Age-Associated Diseases , 2012, Journal of biomedicine & biotechnology.

[25]  G. Shurin,et al.  Tumor associated regulatory dendritic cells. , 2012, Seminars in cancer biology.

[26]  J. Paul Robinson,et al.  Computational analysis of high-throughput flow cytometry data , 2012, Expert opinion on drug discovery.

[27]  P. Chattopadhyay,et al.  Cytometry: today's technology and tomorrow's horizons. , 2012, Methods.

[28]  S. Kuhara,et al.  Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination , 2012, Cancer.

[29]  J. Schlom,et al.  Clinical evaluation of TRICOM vector therapeutic cancer vaccines. , 2012, Seminars in oncology.

[30]  Kanji Takahashi,et al.  Circulating myeloid dendritic cells as prognostic factors in patients with pancreatic cancer who have undergone surgical resection. , 2012, The Journal of surgical research.

[31]  H. Pircher,et al.  Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization , 2012, PLoS ONE.

[32]  Regina K. Cheung,et al.  Screening: CyTOF—the next generation of cell detection , 2011, Nature Reviews Rheumatology.

[33]  A. Pera,et al.  Immunosenescence of Human Natural Killer Cells , 2011, Journal of Innate Immunity.

[34]  Randall E. Brand,et al.  Transcriptional Profiling of Peripheral Blood Mononuclear Cells in Pancreatic Cancer Patients Identifies Novel Genes with Potential Diagnostic Utility , 2011, PloS one.

[35]  D. Tran,et al.  T regulatory cells in cancer: recent advances and therapeutic potential , 2010, Expert opinion on biological therapy.

[36]  Björn Nilsson,et al.  Integrative genomic analysis of HIV-specific CD8+ T cells reveals that PD-1 inhibits T cell function by upregulating BATF , 2010, Nature Medicine.

[37]  Mario Roederer,et al.  OMIPs—Orchestrating multiplexity in polychromatic science , 2010, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[38]  P. Debré,et al.  Human NK cells display major phenotypic and functional changes over the life span , 2010, Aging cell.

[39]  R. Yung,et al.  Leukocyte function in the aging immune system , 2010, Journal of leukocyte biology.

[40]  A. Goldrath,et al.  Surviving the crash: transitioning from effector to memory CD8+ T cell. , 2009, Seminars in immunology.

[41]  C. Galustian,et al.  The effect of colorectal cancer upon host peripheral immune cell function , 2009, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[42]  J. Ouslander,et al.  T cell subset-specific susceptibility to aging. , 2008, Clinical immunology.

[43]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[44]  J. Schlom,et al.  Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer , 2008, Clinical Cancer Research.

[45]  T. Whiteside,et al.  The Frequency and Suppressor Function of CD4+CD25highFoxp3+ T Cells in the Circulation of Patients with Squamous Cell Carcinoma of the Head and Neck , 2007, Clinical Cancer Research.

[46]  Águeda Martínez-Barriocanal,et al.  Molecular and Functional Characterization of CD300b, a New Activating Immunoglobulin Receptor Able to Transduce Signals through Two Different Pathways1 , 2006, The Journal of Immunology.

[47]  L. Walker,et al.  The role of CD28 and cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) in regulatory T‐cell biology , 2006, Immunological reviews.

[48]  T. Whiteside,et al.  Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. , 2006, Seminars in cancer biology.

[49]  Takuma Hayashi,et al.  CD72‐mediated suppression of human naive B cell differentiation by down‐regulating X‐box bindingprotein 1 , 2005, European journal of immunology.

[50]  P. Moss,et al.  The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age , 2005, Clinical and experimental immunology.

[51]  D. E. Faunce,et al.  Aging and innate immune cells , 2004, Journal of leukocyte biology.

[52]  P. Chattopadhyay,et al.  Seventeen-colour flow cytometry: unravelling the immune system , 2004, Nature Reviews Immunology.

[53]  C. Stăvaru,et al.  Evidence for immune defects in breast and lung cancer patients , 2004, Cancer Immunology, Immunotherapy.

[54]  R. Feise Do multiple outcome measures require p-value adjustment? , 2002, BMC medical research methodology.

[55]  P. Debré,et al.  Aiolos and Ikaros: Regulators of lymphocyte development, homeostasis and lymphoproliferation , 2002, Apoptosis.

[56]  A. Barclay,et al.  CD200 and membrane protein interactions in the control of myeloid cells. , 2002, Trends in immunology.

[57]  K. Hirokawa,et al.  Altered T cell signalling in ageing , 2001, Mechanisms of Ageing and Development.

[58]  F. Borrego,et al.  NK phenotypic markers and IL2 response in NK cells from elderly people , 1999, Experimental Gerontology.

[59]  H. Müller-Hermelink,et al.  Admission criteria for immunogerontological studies in man: The senieur protocol , 1984, Mechanisms of Ageing and Development.

[60]  R. Scheuermann,et al.  Elucidation of seventeen human peripheral blood B‐cell subsets and quantification of the tetanus response using a density‐based method for the automated identification of cell populations in multidimensional flow cytometry data , 2010, Cytometry. Part B, Clinical cytometry.

[61]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[62]  M. Fujimoto,et al.  The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system. , 2005, Current directions in autoimmunity.

[63]  P. Kralickova,et al.  CD4+ T-lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours. , 2001, Scandinavian journal of clinical and laboratory investigation.

[64]  S. Sato,et al.  CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. , 1997, Annual review of immunology.